The utility of 2-deoxy-2[18F] fluoro-D-glucose-positron emission tomography and combined positron emission tomography and computed tomography in lymphoma and melanoma

被引：12

作者：

Macapinlac, HA ^{[1
]}

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Div Diagnost Imaging, Houston, TX 77030 USA

来源：

MOLECULAR IMAGING AND BIOLOGY | 2004年 / 6卷 / 04期

关键词：

FDG; PET; lymphoma; melanoma;

D O I：

10.1016/j.mibio.2004.04.002

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

The purpose of this article is to review the clinical utility of FDG and FDG PET/CT imaging in lymphoma and melanoma. A review of the important articles supporting the use of FDG PET imaging in the staging, restaging, and monitoring of response to therapy in lymphoma and melanoma is provided. The intent is to give the nuclear medicine physician and or radiologist the perspective of what may be important clinically to make FDG PET imaging an integral part of the workup of lymphoma and melanoma patients. Specific clinical scenarios and uptake patterns that are unique for lymphoma and melanoma are discussed to ensure relevant and proper interpretation of the FDG PET scans. FDG PET scanning in summary is a useful imaging modality in the staging, restaging, and response evaluation of patients with lymphoma and melanoma. (C) 2004 Elsevier Inc. All rights reserved.

引用

页码：200 / 207

页数：8

共 21 条

[1]

Balch CM, 1999, ANN SURG, V230, P463

[2] Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma [J].

Balch, CM ;

Buzaid, AC ;

Soong, SJ ;

Atkins, MB ;

Cascinelli, N ;

Coit, DG ;

Fleming, ID ;

Gershenwald, JE ;

Houghton, A ;

Kirkwood, JM ;

McMasters, KM ;

Mihm, MF ;

Morton, DL ;

Reintgen, DS ;

Ross, MI ;

Sober, A ;

Thompson, JA ;

Thompson, JF .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) :3635-3648

[3]

Bangerter M, 1999, ACTA ONCOL, V38, P799

[4]

Bangerter M., 1999, RADIOGRAPHY, V5, P155

[5] Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma [J].

Cremerius, U ;

Fabry, U ;

Neuerburg, J ;

Zimny, M ;

Osieka, R ;

Buell, U .

NUCLEAR MEDICINE COMMUNICATIONS, 1998, 19 (11) :1055-1063

[6]

Crippa F, 2000, J NUCL MED, V41, P1491

[7]

GRITTERS LS, 1993, J NUCL MED, V34, P1420

[8] The role of fluorine-18 deoxyglucose positron emission tomography in the management of patients with metastatic melanoma: Impact on surgical decision making [J].

Gulec, SA ;

Faries, MB ;

Lee, CC ;

Kirgan, D ;

Glass, C ;

Morton, DL ;

Essner, R .

CLINICAL NUCLEAR MEDICINE, 2003, 28 (12) :961-965

[9] How morphometric analysis of metastatic load predicts the (un)usefulness of PET scanning:: the case of lymph node staging in melanoma [J].

Mijnhout, GS ;

Hoekstra, OS ;

van Lingen, A ;

van Diest, PJ ;

Adèr, HJ ;

Lammertsma, AA ;

Pijpers, R ;

Meijer, S ;

Teule, GJJ .

JOURNAL OF CLINICAL PATHOLOGY, 2003, 56 (04) :283-286

[10] Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma - A multicenter trial [J].

Morton, DL ;

Thompson, JF ;

Essner, R ;

Elashoff, R ;

Stern, SL ;

Nieweg, OE ;

Roses, DF ;

Karakousis, CP ;

Mozzillo, N ;

Reintgen, D ;

Wang, HJ ;

Glass, EC ;

Cochran, AJ .

ANNALS OF SURGERY, 1999, 230 (04) :453-463

← 1 2 3 →